Merck & Company, Inc.
MRK · NYSE
MRK · NYSE
Merck is a biopharmaceutical company that earns revenue by selling prescription medicines and vaccines. Its portfolio includes oncology treatment KEYTRUDA, Gardasil and newer medicines; oncology and KEYTRUDA are prominent growth drivers in the supplied reporting, but no segment revenue breakdown is provided. Its products serve patients through healthcare systems and medical providers, and its reported results cover worldwide sales. Merck generated $65.0 billion in FY2025 revenue and $18.3 billion in net income, compared with $64.2 billion and $17.1 billion, respectively, in FY2024. Third-quarter 2026 worldwide sales were $18.1 billion, up 5% year over year.
MRK fell 0.62%, from $147.24 to $146.33 across the supplied endpoints. Shares dropped sharply Monday, closing at $140.61 versus Friday’s $145.27, then made only a small recovery Tuesday and slipped again Wednesday; the supplied evidence identifies no company-specific catalyst for that early-week decline. The decisive reversal came Thursday, when the stock rose to $146.33 from $140.93 after Merck reported third-quarter results. Sales beat estimates, worldwide sales grew 5% to $18.1 billion, and the company raised its 2026 earnings and sales outlook. KEYTRUDA demand and newer medicines supported the outlook, although the quarter’s income declined year over year and Merck cited a lower tax rate as a factor in lifting guidance.
Merck fell 1.25%, from $145.45 to $143.63, over the period shown. The path was volatile: shares dropped to $141.98 on October 13, rebounded to $147.37 the next day, then retreated and finished lower on October 19. The clearest company-specific pressure in the supplied coverage was reporting that Merck and Moderna shares dropped amid a leak of melanoma cancer-vaccine trial data; RBC Capital reiterated its Merck rating on the melanoma data, but the snippet does not disclose the rating or a target. A wider EU bladder-cancer label for Keytruda was a potential positive, although the coverage also highlighted the need for further ESMO data. No market benchmark is provided to assess broader-market effects.
Merck gained 4.24%, rising from $139.54 to $145.45 across the supplied closes. The shares advanced through October 7, edged lower on October 8, then climbed to $145.60 on October 9 before slipping 15 cents on October 12. The evidence does not tie those moves to a dated company-specific catalyst. Barron’s described a broader healthcare rally that included Merck, Eli Lilly and AbbVie, providing sector context for the rise; the supplied evidence does not establish that this alone drove Merck’s gains. A report on promising Keytruda and personalized mRNA-vaccine skin-cancer trial results also appears in the evidence, but without a date or details linking it to the week’s trading.
MRK fell 4.92%, from $149.28 to $141.94 across the supplied closes. The largest pressure came amid reports that Merck’s injectable Keytruda was barred in Europe and that the drug faced a legal setback, raising concerns around its key growth product. Shares declined from $149.28 on September 29 to $143.81 on October 1, recovered slightly to $144.30 on October 2, then dropped to $139.54 on October 5. On October 6 they rebounded 1.72% to $141.94; Zacks described the stock as beating a broader market upswing that day. The rebound recovered only part of the earlier losses, leaving the stock down over the period.
Merck fell 2.82%, from $147.98 to $143.81. Shares edged up from $148.69 on Monday to $149.28 on Tuesday, then reversed sharply: Wednesday’s close of $145.31 was a 2.66% daily decline, followed by a further drop to $143.81 on Thursday. The supplied evidence does not tie that reversal to a specific company announcement; Zacks reported the Wednesday decline and said Merck fell more than the broader market, but its snippet gives no cause. Merck had positive pipeline news, including a phase IIb tulisokibart result and a KRAS G12D licensing deal, while partners also withdrew an FDA filing for a lung-cancer therapy. The evidence does not establish that any of these developments drove the week’s trading.
MRK gained 2.19%, rising from $144.91 on September 16 to $148.08 on September 23. It climbed to $149.50 on September 21 and $150.91 on September 22, then fell 1.88% on September 23, giving back much of the two-session advance. The supplied headlines present mixed company news: Daiichi Sankyo and Merck withdrew the ifinatamab deruxtecan BLA, while a report highlighted a 26% reduction in the risk of worsening or death with Merck’s kidney-cancer drug pair. The evidence does not date those headlines well enough to connect either to a particular session or attribute the weekly gain to them. No broad-market comparison is supplied, so market context cannot be assessed.
Merck fell $5.48, or 3.65%, from $150.33 to $144.85 over the week. The supplied evidence does not identify a company-specific announcement, analyst action, earnings release, or guidance change that explains the decline. Trading had already weakened from $150.33 on September 4 to $143.93 on September 11, including a $2.82 drop on September 10, before the stock recovered modestly on September 14. The move therefore appears to have reflected continued selling pressure rather than a clearly documented new catalyst. Available articles frame the central issues as valuation, dividend sustainability, Keytruda’s growth and trial expansion, and whether Merck’s pipeline can offset future pressure, but none is tied to a dated event during this week. Broader market context is not supplied.
Merck shares gained 0.47%, rising from $147.76 to $148.46, despite a sharp late-week reversal. The stock had climbed from $149.86 on September 1 to $152.34 on September 3, but gave back most of that advance with a 1.32% drop on September 4 and another 1.24% decline on September 8. The supplied evidence does not identify a company-specific announcement driving the move. Instead, coverage portrayed Merck as relatively flat while Moderna rallied, suggesting muted sector-relative performance. Investor attention remained centered on Keytruda’s eventual loss of exclusivity, pipeline progress, and whether newer cancer drugs can offset that exposure, while analyst target increases provided some support.
Merck rose 1.87%, from $149.54 to $152.34 over the week. The stock first fell to $147.76 on Monday, extending the prior Friday’s decline, then reversed higher for three consecutive sessions, gaining $4.58 from Monday’s close through Thursday. The strongest apparent company-specific support was Wells Fargo maintaining its Merck view while raising its price target to $170, although the supplied evidence does not establish that the action directly drove any particular session. Investors also weighed longer-term product risks, including another Alzheimer’s trial cancellation under the Neuphoria partnership and debate over Keytruda’s durability. The record provides no clear market-wide catalyst or evidence linking those reports to the daily moves, so the week was primarily a recovery after Monday’s dip.
Merck finished the comparison period up $0.55, or 0.37%, at $149.54 from $148.99. The week was materially more volatile than the net change suggests: shares fell 1.24% on Monday from Friday’s $152.55 close, jumped 3.84% on Tuesday to $156.45, then gave back the entire advance over the next two sessions, falling 4.41% to Thursday’s close. Coverage cited positive melanoma data, pipeline progress, new launches and M&A as support for the rally, while Argus raised its target to $170. A court rejection of Merck’s challenge to Medicare drug-price negotiation was a counterweight. No single dated company announcement explains the full reversal, and volume fell sharply late in the period.
Merck gained $13.44, or 9.92%, over the measured week, rising from $135.55 to $148.99. Shares were essentially flat through Tuesday, closing at $135.97 on Monday and slipping to $135.17 on Tuesday. The decisive catalyst arrived Wednesday, when Merck and Moderna reported a positive Phase III readout for their personalized melanoma therapy, intismeran, showing improved recurrence-free and distant metastasis-free survival; volume surged to 32.8 million shares and the stock closed at $152.20. Merck gave back $3.21 on Thursday, a partial reversal, as investors appeared to consolidate the sharp gain. Lower bond yields and generally supportive equity-market conditions helped the backdrop, but the cancer-therapy news was the material company-specific driver.
MRK rose $3.15, or 2.47%, from $127.77 to $130.92 over the week, with nearly all of the gain arriving on Monday, when the stock advanced $2.34. The clearest company-related support was coverage highlighting Merck’s raised guidance and new KEYTRUDA developments, alongside reports that pipeline progress could lift fair value. The stock then added modestly through Friday, gaining $0.21 on Tuesday, $0.33 on Wednesday, $0.04 on Thursday and $0.21 on Friday, without a material reversal. Trading volume declined from 11.2 million shares on August 3 to 6.0 million on August 10, suggesting the late-week advance occurred on lighter activity. No separate, named analyst rating action was supplied.
-2.90%, from $131.82 to $128.00. Merck declined through July 30, briefly recovered to $130.20 on July 31, then fell 1.87% to $127.77 on August 3 before edging up to $128.00 on August 4. The only identified company-specific catalyst was second-quarter reporting: Merck beat earnings and revenue estimates, raised and narrowed its 2026 sales outlook, and cited strong oncology and newer-product performance. Those positives were tempered by a $1.3 billion GAAP quarterly loss, versus $4.4 billion of profit a year earlier, and a $0.54 loss per share. Because the largest decline preceded the August 4 release, the supplied evidence does not establish that the earnings details caused the weekly drop.
